A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age
Phase 4
Completed
NCT06634797
| Condition | Healthy Volunteers |
|---|
| Phase | Phase 4 |
|---|
| Sponsor | ModernaTX, Inc. |
|---|
| Status | Completed |
|---|
| Enrollment | 1,000 participants |
|---|
| Interventions | mRNA-1273.712 |
|---|
| Start date | Oct 8, 2024 |
|---|
| Completion date | Jan 20, 2025 |
|---|
| Results posted | Feb 4, 2026 |
|---|
Summary
The primary objective of this study is to assess cardiac troponin I (cTnI) values in participants who received mRNA-1273.712 or placebo.
Number of Participants With Elevated Cardiac Troponin I (cTnI) at Day 4 or Day 32 (3 Days After Injection 1 or Injection 2)
Day 4 and Day 32 · Participants
| mRNA-1273.712 | 1 Participants |
|---|
| Placebo | 0 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.